What is the clinical evidence from this study?

Study design: Cohort. Population: Coronary Artery Disease (n=98). Intervention: Insulin resistance (HOMA-IR ≥ 2.6) vs. HOMA-IR < 2.6. Primary outcome: 30-day major adverse cardiac events (MACE) (OR 49.27, 95% CI 1.05-231.13, p=0.048).

January 1, 2006Journal of Korean Medical ScienceOpen Access

The Effect of Insulin Resistance on Prognosis of Non-Diabetic Patients Who Underwent Percutaneous Coronary Intervention

Q: What are the key findings of this study?

In non-diabetic patients undergoing percutaneous coronary intervention, insulin resistance (HOMA-IR ≥ 2.6) was an independent predictor of 30-day major adverse cardiac events (OR 49.27).

Q: What does this research mean for the field?

Insulin resistance (HOMA-IR ≥ 2.6) is an independent predictor of short-term major adverse cardiac events in non-diabetic patients undergoing percutaneous coronary intervention. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Insulin resistance linked to ~49-fold higher 30-day MACE risk in non-diabetic PCI patients.

OR 49.27
95% CI 1.05-231.13
P=0.048
n=98

Why the study?

There was no data regarding the clinical effect of insulin resistance on outcomes of PCI in non-diabetic patients.

Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?

Population

98 non-diabetic consecutive patients undergoing elective coronary angiography

Comparison

HOMA-IR ≥ 2.6 (insulin resistance) vs HOMA-IR < 2.6

Design

Cohort study

Follow-up

30-day

Authors

KYKyeong Ho YunInterventional / Structural Cardiology MJMyung Ho JeongInterventional Cardiology KKKye Hun KimChonnam National University

Discussion

Member takes

Overview

HOMA-IR may aid post-PCI risk stratification in non-diabetics; leaves open whether targeting insulin resistance improves outcomes.

Study Design

Type

Cohort (n=98)

Multicenter

Structured PICO

Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?

Population

98 non-diabetic patients with chest pain undergoing diagnostic coronary angiography, 59 of whom underwent percutaneous coronary intervention, followed for 30 days.

Exposure

Insulin resistance defined as HOMA-IR >= 2.6 (n=27)

Comparator

No insulin resistance defined as HOMA-IR < 2.6 (n=71)

Outcome

In-hospital and 30-day major adverse cardiac events (MACE)composite

Main Result

Odds Ratio: 49.27 (95% CI 1.05–231.13)

Absolute Event Rate: 27.8% vs 2.4%

p-value: p=0.048

Increased insulin resistance (HOMA-IR >= 2.6) is an independent predictor of short-term MACE in non-diabetic patients undergoing elective coronary angiography and PCI.

Limitations

Small number of patients
Short follow-up period
Lack of reproducibility testing as HOMA-IR was not measured repetitively during admission

Cite This Study

Yun et al. (2006) conducted a cohort in Coronary Artery Disease (n=98). Insulin resistance (HOMA-IR ≥ 2.6) vs. HOMA-IR < 2.6 was evaluated on 30-day major adverse cardiac events (MACE) (OR 49.27, 95% CI 1.05-231.13, p=0.048). In non-diabetic patients undergoing percutaneous coronary intervention, insulin resistance (HOMA-IR ≥ 2.6) was an independent predictor of 30-day major adverse cardiac events (OR 49.27).

synapsesocial.com/papers/6aaa2d2478e2697aa3f6b766 https://doi.org/10.3346/jkms.2006.21.2.212

View Full Paper

Ask AI

Bookmark

January 1, 2006Journal of Korean Medical ScienceOpen Access

The Effect of Insulin Resistance on Prognosis of Non-Diabetic Patients Who Underwent Percutaneous Coronary Intervention

View Full Paper

Ask AI

Bookmark

Key result

Insulin resistance linked to ~49-fold higher 30-day MACE risk in non-diabetic PCI patients.

OR 49.27
95% CI 1.05-231.13
P=0.048
n=98

Why the study?

There was no data regarding the clinical effect of insulin resistance on outcomes of PCI in non-diabetic patients.

Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?

Population

98 non-diabetic consecutive patients undergoing elective coronary angiography

Comparison

HOMA-IR ≥ 2.6 (insulin resistance) vs HOMA-IR < 2.6

Design

Cohort study

Follow-up

30-day

Authors

KYKyeong Ho YunInterventional / Structural Cardiology MJMyung Ho JeongInterventional Cardiology KKKye Hun KimChonnam National University

Discussion

Member takes

Overview

HOMA-IR may aid post-PCI risk stratification in non-diabetics; leaves open whether targeting insulin resistance improves outcomes.

Study Design

Type

Cohort (n=98)

Multicenter

Structured PICO

Does insulin resistance (HOMA-IR >= 2.6) increase the risk of MACE in non-diabetic patients undergoing elective coronary angiography and PCI?

Population

98 non-diabetic patients with chest pain undergoing diagnostic coronary angiography, 59 of whom underwent percutaneous coronary intervention, followed for 30 days.

Exposure

Insulin resistance defined as HOMA-IR >= 2.6 (n=27)

Comparator

No insulin resistance defined as HOMA-IR < 2.6 (n=71)

Outcome

In-hospital and 30-day major adverse cardiac events (MACE)composite

Main Result

Odds Ratio: 49.27 (95% CI 1.05–231.13)

Absolute Event Rate: 27.8% vs 2.4%

p-value: p=0.048

Increased insulin resistance (HOMA-IR >= 2.6) is an independent predictor of short-term MACE in non-diabetic patients undergoing elective coronary angiography and PCI.

Limitations

Small number of patients
Short follow-up period
Lack of reproducibility testing as HOMA-IR was not measured repetitively during admission

Cite This Study

synapsesocial.com/papers/6aaa2d2478e2697aa3f6b766 https://doi.org/10.3346/jkms.2006.21.2.212

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark